171 related articles for article (PubMed ID: 7101243)
21. [The platelet defect in myeloproliferative disorder (author's transl)].
Delobel J
Nouv Rev Fr Hematol (1978); 1976; 16(3):443-6. PubMed ID: 1012918
[TBL] [Abstract][Full Text] [Related]
22. Abnormal platelet serotonin uptake and binding sites in myeloproliferative disorders.
Caranobe C; Sié P; Fernandez F; Pris J; Moatti S; Boneu B
Thromb Haemost; 1984 Jul; 51(3):349-53. PubMed ID: 6593892
[TBL] [Abstract][Full Text] [Related]
23. [Platelet defects in chronic myeloproliferative disorders].
Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
[TBL] [Abstract][Full Text] [Related]
24. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
Ryningen A; Apelseth T; Hausken T; Bruserud Ø
Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
[TBL] [Abstract][Full Text] [Related]
25. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
[TBL] [Abstract][Full Text] [Related]
26. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
27. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
Okuma M
Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
[No Abstract] [Full Text] [Related]
28. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
[TBL] [Abstract][Full Text] [Related]
29. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders.
Okuma M; Uchino H
Blood; 1979 Dec; 54(6):1258-71. PubMed ID: 116695
[TBL] [Abstract][Full Text] [Related]
30. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production.
Cattaneo M; Lombardi R; Zighetti ML; Gachet C; Ohlmann P; Cazenave JP; Mannucci PM
Thromb Haemost; 1997 May; 77(5):986-90. PubMed ID: 9184415
[TBL] [Abstract][Full Text] [Related]
31. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases.
Viero P; Cortelazzo S; Bassan R; Barbui T
Thromb Haemost; 1982 Oct; 48(2):125-6. PubMed ID: 6184841
[TBL] [Abstract][Full Text] [Related]
32. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders.
Russell NH; Salmon J; Keenan JP; Bellingham AJ
Thromb Res; 1981 May; 22(4):389-97. PubMed ID: 6794179
[No Abstract] [Full Text] [Related]
33. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
Zuk E
Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
[TBL] [Abstract][Full Text] [Related]
34. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
35. Evidence for a platelet membrane defect in the myeloproliferative syndromes.
Castaldi PA; Berndt MC; Booth W; Gregory C; Bull H; Greaves M
Thromb Res; 1982 Sep; 27(5):601-9. PubMed ID: 6960545
[TBL] [Abstract][Full Text] [Related]
36. Increased platelet aggregation following splenectomy in patients with myeloproliferative disease.
Aviram M; Carter A; Tatarsky I; Levy Y; Brook JG
Isr J Med Sci; 1985 May; 21(5):415-7. PubMed ID: 4019124
[TBL] [Abstract][Full Text] [Related]
37. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests.
Boneu B; Nouvel C; Sie P; Caranobe C; Combes D; Laurent G; Pris J; Bierme R
Scand J Haematol; 1980 Sep; 25(3):214-20. PubMed ID: 7466310
[TBL] [Abstract][Full Text] [Related]
38. Platelets in the myeloproliferative syndrome.
Weinfeld A; Branehög I; Kutti J
Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
[No Abstract] [Full Text] [Related]
39. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
Berild D; Hasselbalch H; Knudsen JB
Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
[TBL] [Abstract][Full Text] [Related]
40. Exploration of mechanisms of amine storage in the dense bodies of human platelets.
Costa JL; Eanes ED
Res Commun Chem Pathol Pharmacol; 1984 Sep; 45(3):347-66. PubMed ID: 6095385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
